长江医药控股股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 特别风险提示： 证券代码：300391 证券简称：长药控股 公告编号：2023-063 本次担保后，公司及控股子公司提供担保总余额为人民币94,683.65万元， 占公司最近一期经审计净资产的比例为118.26%，公司及控股子公司提供担保总 额超过最近一期经审计净资产100%，请投资者充分关注担保风险。 一、担保情况概述 长江医药控股股份有限公司（以下简称"公司"、"长药控股"）于2023年4月 27日召开第五届董事会第八次会议、于2023年5月24日召开的2022年年度股东大 会，审议通过了《关于公司及子公司2023年度向银行申请综合授信额度暨公司与 子公司及子公司之间相互担保额度的议案》，2023年公司拟为各级全资和控股子 公司提供合计不超过人民币157,000万元的新增担保额度，其中，对资产负债率 未超过70%的子公司提供的新增担保额度为不超过人民币65,000万元，对资产负 债率超过70%的子公司提供的新增担保额度为不超过人民币92,000万元； ...

证券代码：300391 证券简称：长药控股 公告编号：2023-061 长江医药控股股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、董事会会议召开情况 长江医药控股股份有限公司（以下简称"公司"）第五届董事会第十次会议于 2023年8月14日以通讯表决方式召开，会议通知已于2023年8月9日以电子邮件形式 送达。本次会议由李金凤女士主持，应参与表决董事9人，实际参与表决董事9人。 本次会议召集、召开的程序、方式符合有关法律、行政法规、部门规章、规范性文 件和公司章程规定。 二、董事会会议审议情况 关于聘任财务总监的议案。 特此公告。 长江医药控股股份有限公司董事会 2023年8月14日 公司独立董事对本议案发表了同意的独立意见。 详情参见与本公告同日披露于巨潮资讯网的《关于变更财务总监的公告》。 表决情况：赞成：9票；反对：0票；弃权：0票 表决结果：通过。 三、备查文件 1、公司第五届董事会第十次会议决议； 2、独立董事关于第五届董事会第十次会议相关事项的独立意见； 3、深交所要求的其他文件。 1 ...

证券代码：300391 证券简称：长药控股 公告编号：2023-062 长江医药控股股份有限公司 关于变更财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、关于公司财务总监辞职的情况 长江医药控股股份有限公司（以下简称"公司"）董事会于近日收到财务总监 胡正盈先生递交的书面辞职报告。胡正盈先生因个人原因辞去公司财务总监职务， 辞职后不再担任公司及子公司任何职务。根据《公司法》及《公司章程》等相关规 定，胡正盈先生的辞职报告于送达董事会之日起生效。 胡正盈先生原定任期为2022年7月11日至2025年7月11日。截至本公告披露日， 胡正盈先生未持有公司股份，不存在股份转让承诺，不存在其他应当履行而未履行 的承诺事项。 胡正盈先生在任职期间严谨务实、恪尽职守、勤勉尽责，公司及董事会对胡正 盈先生为公司发展所做出的贡献表示衷心的感谢。 二、关于公司聘任财务总监的情况 根据公司治理的需要，为确保公司财务管理工作的顺利开展，经公司总经理提 名，公司董事会提名委员会资格审查通过，公司于2023年8月14日召开第五届董事 会第十次会议，审议通过了《关于聘任 ...

综上所述，全体独立董事一致同意聘任杨英环女士为公司财务总监。 专此意见。 长江医药控股股份有限公司 独立董事：邓远军、兰霞、吴康兵 2023 年 8 月 14 日 关于第五届董事会第十次会议相关事项的独立意见 根据《深圳证券交易所创业板股票上市规则》、《关于在上市公司建立独立董事制度的 指导意见》等有关法律、法规以及《长江医药控股股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，作为长江医药控股股份有限公司（以下简称"公司"）的独立 董事，现对公司聘任财务总监发表如下独立意见： 经审阅杨英环女士的资料，未发现有《公司法》规定的不得担任公司财务总监的情形。 杨英环女士未被中国证监会采取证券市场禁入措施，未被证券交易所公开谴责，不存在涉 嫌犯罪被司法机关立案侦查或者涉嫌违法违规被中国证监会立案调查的情形，任职资格均 符合《公司法》、《深圳证券交易所创业板股票上市规则》等法律法规及规范性文件和《公 司章程》的有关规定，具备担任上市公司财务总监的资格，能够胜任所聘岗位职责要求。 本次聘任事项的提名、聘任程序符合《公司法》、《公司章程》等有关规定，合法有效。 长江医药控股股份有限公司独立董事 ...

长江医药控股股份有限公司 关于控股股东协议转让股份的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、本次股份转让事项的基本情况 2023年6月14日，长江医药控股股份有限公司（以下简称"公司"）控股股 东长兴盛世丰华商务有限公司（以下简称"盛世丰华"）与上海驭聪资产管理有 限公司（以下简称"上海驭聪"）作为基金管理人的驭聪天顺贰号私募证券投资 基金（以下简称"天顺贰号"）签署《股份转让协议》，将其持有的公司21,000,000 股股份以7.34元/股的价格，通过协议转让的方式转让给天顺贰号；同日，盛世 丰华与上海驭聪（代表天顺贰号）签署《一致行动人协议》，双方构成一致行动 关系。2023年7月21日，本次协议转让完成股份过户登记。本次股份转让后，盛 世丰华仍为公司控股股东。 具体内容详见公司于2023年6月15日、2023年6月21日、2023年7月25日在巨 潮资讯网披露的《关于控股股东增加一致行动人及在一致行动人内部协议转让股 份暨权益变动的提示性公告》、《简式权益变动报告书（一）》、《简式权益变 动报告书（二）》、《关于深圳证券交易所关注函回 ...

| 艺、成品质量、稳定性等研究，即将完成药理毒理试验。目前没有销 | | --- | | 售。谢谢！ | | 10、请问罗总长药控股去年 亿未收款都是长江星账面利润吗？ 14 | | 还有罗总已成为失信被执行人还担任公司高管，不影响公司声誉吗？ | | 回复：尊敬的投资者您好，公司已采取措施加强现金流管理，对 | | 回款不及时的客户适当控制发货量，以提高回款工作效果，改善公司 | | 现金流状况。罗总受关联公司影响成为失信被执行人，相关问题在逐 | | 步解决。谢谢！ | | 11、作为上市公司的懂事总经理您作为失信人会不会对公司的业 | | 务产生较大的影响？ | | 回复：尊敬的投资者您好，本人作为失信人问题正在逐步解决， | | 对公司业务不会产生影响。谢谢！ | | 12、请问罗总，各地零散疫情发生，对长药而言业务而言是否有 | | 推动，公司会有哪些动作？ | | 回复：尊敬的投资者您好，公司将按照战略规划和未来经营思路 | | 积极推动公司业务发展，详细内容参见公司 2022 年年度报告中的相关 | | 内容。谢谢！ | | 13、公司有多少药品问号，有多少在研品种？ | | 回复：尊敬的投资者 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥136,792,880.94, a decrease of 74.92% compared to ¥545,403,773.14 in the same period last year[5] - The net profit attributable to shareholders was -¥22,958,141.64, representing a decline of 256.75% from a profit of ¥14,645,911.14 in the previous year[5] - Total operating revenue for the current period is $136.79 million, a decrease of 75.1% compared to $545.40 million in the previous period[17] - Operating profit for the current period is a loss of $31.87 million, compared to a profit of $51.54 million in the previous period[18] - Net profit for the current period is a loss of $30.81 million, significantly lower than the profit of $50.23 million in the previous period[18] - Basic and diluted earnings per share for the current period are both -$0.0655, compared to $0.0418 in the previous period[18] Cash Flow - The net cash flow from operating activities was ¥24,341,147.26, an increase of 158.18% compared to -¥41,839,544.89 in the same period last year[5] - Cash flow from operating activities shows a net inflow of $24.34 million, contrasting with a net outflow of $41.84 million in the previous period[21] - The cash flow from financing activities showed a net outflow of -¥32,243,798.34, a decline of 116.61% compared to a net inflow of ¥194,088,746.52 in the previous year[8] - The company reported a net cash outflow from financing activities of $32.24 million, compared to an inflow of $194.09 million in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,668,309,118.72, reflecting a 2.51% increase from ¥3,578,587,920.62 at the end of the previous year[5] - The company's current assets totaled CNY 1,843,486,887.61, up from CNY 1,741,651,648.89 at the start of the year, indicating a growth of approximately 5.9%[14] - The total liabilities increased to CNY 2,034,501,520.14 from CNY 1,913,967,101.32, reflecting a rise of about 6.3%[15] - The company's cash and cash equivalents decreased to CNY 12,628,606.41 from CNY 17,474,790.79, representing a decline of approximately 27.5%[14] - The total non-current liabilities rose to CNY 390,477,474.99 from CNY 368,916,000.79, reflecting an increase of about 5.8%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,545, with no preferred shareholders[10] - The total equity attributable to the owners of the parent company decreased to CNY 777,714,584.27 from CNY 800,672,725.91, a decline of about 2.9%[15] Research and Development - Research and development expenses decreased by 75.35% to ¥2,011,134.43 from ¥8,157,597.25 in the previous year, attributed to the absence of the internal combustion engine segment[8] Inventory and Receivables - Accounts receivable stood at CNY 1,413,212,332.63, slightly down from CNY 1,428,970,534.49, showing a decrease of about 1.1%[14] - Inventory increased to CNY 71,590,247.89 from CNY 59,473,798.20, marking an increase of approximately 20.3%[14] Sales Performance - The company received $162.19 million in cash from sales of goods and services, a decrease from $480.15 million in the previous period[21] - Total operating costs for the current period are $161.38 million, down from $482.57 million, reflecting a reduction of 66.6%[17]

Financial Performance - The company's operating revenue for 2022 was ¥1,615,322,934.59, a decrease of 31.61% compared to ¥2,361,946,450.06 in 2021[24]. - The net profit attributable to shareholders was a loss of ¥23,273,315.49 in 2022, representing a decline of 147.40% from a profit of ¥49,104,524.78 in 2021[24]. - The cash flow from operating activities showed a net outflow of ¥66,075,132.38, down 128.61% from ¥230,987,890.32 in the previous year[24]. - The total assets at the end of 2022 were ¥3,578,587,920.62, a decrease of 15.09% from ¥4,214,473,787.82 at the end of 2021[24]. - The company reported a basic earnings per share of -¥0.0664 for 2022, a drop of 147.36% compared to ¥0.1402 in 2021[24]. - The company's total revenue for 2022 was ¥1,615,322,934.5, a decrease of 31.61% compared to ¥2,361,946,450.0 in 2021[62]. - The pharmaceutical sector accounted for 78.54% of total revenue in 2022, generating ¥1,268,718,910.9, down 18.59% from ¥1,558,351,427.3 in 2021[62]. - The company reported a significant decline in revenue from the internal combustion engine parts sector, which fell by 59.41% to ¥190,527,216.42 in 2022[62]. - The sales of traditional Chinese medicine pieces contributed significantly to revenue stability, with a total of ¥1,030,604,659.6, down 9.17% from the previous year[62]. - The company achieved a net profit of 123.8 million yuan for the year 2022, reflecting a 1% increase compared to the previous year[103]. Operational Changes - The company accelerated its transformation by divesting its underperforming internal combustion engine parts business, which saw a cumulative sales volume of 21.45 million units, a year-on-year decrease of 14.42%[53]. - The company is engaged in a significant asset restructuring involving the acquisition of a 52.7535% stake in Changjiang Star[15]. - The company has focused on divesting non-core assets, including the sale of shares in several subsidiaries to enhance operational efficiency and reduce management costs[106]. - The company has established a nationwide procurement network for traditional Chinese medicine raw materials, ensuring timely procurement of quality materials to meet customer demands[49]. - The company has established a public bonded warehouse in the health industry park to enhance international trade capabilities and support local economic growth[58]. Market and Industry Outlook - The Chinese herbal medicine market has become the second largest market in the traditional Chinese medicine industry, with significant regulatory policies introduced in 2022 to strengthen oversight[37]. - By 2030, it is projected that there will be approximately 250 million individuals aged 65 and older in China, accounting for 16.9% of the population, indicating a substantial growth potential for the pharmaceutical market[37]. - The photovoltaic industry saw a new installed capacity of 87.41 GW in 2022, representing a year-on-year growth of 59.3%[39]. - The Chinese traditional medicine market is expected to exceed RMB 1 trillion in 2023 and may surpass RMB 4 trillion by 2025, indicating significant growth potential over the next 20 to 30 years[113]. - The Chinese herbal medicine processing industry is projected to reach a market size of over RMB 530 billion by 2025, with an annual growth rate of over 10%[110]. Research and Development - The company is investing CNY 1.3 billion in the Ningxia Changjiang Pharmaceutical Guoyuan Six Plateau Modern Traditional Chinese Medicine Health Industry Park project, which includes six sub-projects[56]. - The company is developing a new electric heating laminator, which offers advantages such as faster heating speed and better safety compared to traditional oil heating methods[52]. - The company aims to strengthen its core business in traditional Chinese medicine by expanding its scale in GAP planting, processing, and production of traditional Chinese medicine pieces[114]. - The company plans to build a traditional Chinese medicine research and development center in collaboration with local universities to develop new traditional Chinese medicine products and improve product quality[114]. - The company is committed to advancing the modernization of traditional Chinese medicine processing technology to enhance the quality of traditional Chinese medicine pieces and medicinal capsules[114]. Governance and Compliance - The company has a robust information disclosure management system, ensuring timely and accurate information dissemination to investors[126]. - The company has implemented a registration management system for insider information, enhancing control over sensitive information[127]. - The company has committed to avoiding any competition with its controlling shareholder, as evidenced by a formal commitment letter[129]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management[128]. - The company has committed to maintaining high standards of corporate governance and transparency following the recent management changes[135]. Financial Strategy and Investments - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the reporting period[156]. - The company has committed to maintaining a sound financial policy to safeguard the assets and funds of the company while maximizing shareholder interests[171]. - The company has established multiple channels for investor relations management, including the Shenzhen Stock Exchange's interactive platform[167]. - The company has committed to ensuring the independence of its operations, including assets, personnel, finance, and business, following the completion of the equity change[184]. - The company guarantees that the commitments made will remain effective until the transfer of all shares held by the controlling shareholder[184]. Risks and Challenges - The company faces risks from macroeconomic cycles and national industrial policies, which could impact product demand and operational performance[117]. - High accounts receivable pose a risk to cash flow, with efforts in place to manage and control the scale of receivables[118]. - Fluctuations in raw material prices significantly affect operating costs, prompting the company to adjust procurement strategies and optimize processes[119]. - The company has a high total amount of external guarantees, exceeding its latest audited net assets, which poses potential risks of overdue guarantees[119]. - The company has made significant investments in new pharmaceutical sectors, which may present integration risks if management capabilities do not meet business needs[118].

证券代码：300391 证券简称：长药控股 公告编号：2023-036 长江医药控股股份有限公司 关于举行2022年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"）《2022年年度报告》已于 2023年4月27日经公司第五届董事会第八次会议审议通过，详细内容请见2023年4 月28日刊登于《证券时报》、《中国证券报》、《证券日报》、《上海证券报》 与巨潮资讯网的年报相关信息。 公司定于2023年5月16日（星期二）下午3：00-5：00，在全景网举行2022 年度网上业绩说明会。本次年度业绩说明会采用网络远程的方式举行，投资者可 登陆"全景·路演天下"（http://rs.p5w.net）参与本次年度业绩说明会。 届时，公司独立董事吴康兵、董事总经理罗明先生、董事副总经理兼董事会 秘书宁潞宏先生、副总经理杨月晓先生、财务总监胡正盈先生将出席本次说明会。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5 ...

编号：2015-04-30-1 证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|----------------------------|--------------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | | 渤海证券（汽车行业高级分析师）：郑连声 | | 及人员姓名 | | | | 时间 | 2105 年 4 月 30 | 日 9:30-13:30 | | 地点 | 公司会议室 | | | 上市公司接待 | 总经理：郭晓伟 | | | 人员姓名 | 董秘：杨金玉 | | | 投资者关系活 | 本次活动采用问答方式进行。 | | | 动主要内容介 | 1. | 公司目前 ...